Literature DB >> 9333089

Femoral artery occlusion in Cavalier King Charles Spaniels.

J W Buchanan1, A W Beardow, C D Sammarco.   

Abstract

OBJECTIVE: To investigate development of femoral artery occlusion in Cavalier King Charles Spaniels.
DESIGN: Prospective study. ANIMALS: 954 Cavalier King Charles Spaniels. PROCEDURE: 1,750 cardiovascular examinations consisting of visual inspection of mucous membranes, thoracic auscultation in areas associated with the heart valves, thoracic palpation, and palpation of the femoral arteries were made at 10 dog shows on 954 dogs. Findings of clinically normal, weak, or undetectable femoral pulses were recorded. Pathologic changes in occluded femoral arteries of 2 dogs were examined histologically.
RESULTS: Of the 954 dogs, 22 (2.3%) had an undetectable right or left femoral pulse on 1 or more examinations. Forty (4.2%) additional dogs had weak unilateral or bilateral femoral pulses. Only 1 dog had exercise intolerance, and it had coexistent congestive heart failure. Histologic examination of serial sections of an occluded femoral artery from 1 dog revealed intimal thickening with breaks in the internal elastic lamina proximal to the occluded segment. The occluded segment of the femoral artery was contracted and filled with an organizing, recanalizing thrombus. Similar histopathologic changes were found in sections of a femoral artery from another dog. CLINICAL IMPLICATIONS: Femoral artery occlusion is rare in other breeds and is not clinically important in dogs because of adequate collateral circulation; however, its rather common development in Cavalier King Charles Spaniels indicates a genetic predisposition and probable weakness in the femoral artery wall.

Entities:  

Mesh:

Year:  1997        PMID: 9333089

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  1 in total

1.  Aortic thromboembolism in a basset hound-beagle crossbred dog with protein-losing nephropathy.

Authors:  Kathryn Gardiner
Journal:  Can Vet J       Date:  2020-03       Impact factor: 1.008

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.